Pharmaceutical company Vicore Pharma Holding AB reported on Wednesday the receipt of patent from the US Patent and Trademark Office (USPTO) for the treatment of infections caused by Severe Acute Respiratory Syndrome (SARS), coronavirus (CoV) and SARS-CoV-2.

The US patent, which has been assigned the number US11,123,329, covers the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.

C21/CoV is covered by patent protection in the US market until December 2040. A major clinical impact of C21 on respiratory function in COVID-19 was documented in a phase 2 trial showing that C21 reduced the need for supplemental oxygen in hospitalized patients by 90%. The company's ongoing international pivotal phase 3 study in 600 COVID-19 patients is expected to deliver top-line data in H1 2022.

Additionally, C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the protective arm of the renin-angiotensin system leading to resolution and regeneration following tissue damage, concluded the company.